Sedative Action of Subcutaneously Infused Midazolam in Rats.
|
Accession number;00A0299951
|
| Title;Sedative Action of Subcutaneously Infused Midazolam in Rats. |
| Author;
SUZUKI MASANORI
(Yamanochiseiyaku Yakuriken)
SATO SHUICHI
(Yamanochiseiyaku Yakuriken)
SASAMATA MASAO
(Yamanochiseiyaku Yakuriken)
FUJIHARA AKIRA
(Yamanochiseiyaku Yakuriken)
MIYATA KEIJI
(Yamanochiseiyaku Yakuriken)
TAKAHASHI IKUO
(Panafamu・raboratorizu Taishayakuriken)
KIMURA RIKUKO
(Yamanochiseiyaku Yakuriken)
|
Journal Title;Pharmacometrics
|
Journal Code:S0617A
|
ISSN:0300-8533
|
|
VOL.58;NO.2;PAGE.45-51(1999)
|
| Figure&Table&Reference;FIG.2, TBL.5, REF.4 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;After a 2-week continuous subcutaneous infusion of imidazobenzodiazepine derivative midazolam* at doses of 0.06, 0.2 and 0.6 mg/rat/hr, rats were assessed for indication of sedation using touch response, spontaneous activity and reactivity tests such as exploratory behavior, and indications of analgesia using a pain response test. Midazolam reduced touch response, spontaneous activity and reactivity, beginning 4-6 hr after administration of 0.2 mg/rat/hr s.c, or 2 hr after administration of 0.6 mg/rat/hr s.c. These decreases in touch response and spontaneous activity observed at doses of 0.2 mg/rat/hr s.c. and in touch response, spontaneous activity and reactivity observed at doses of 0.6 mg/rat/hr s,c. remained essentially constant during the 2-week test period. The number of animals exhibiting touch response depression 6 hr, 4 and 7 days after the start of administration increased dose-dependently. This increase reached significance beginning at 0.2 mg/rat/hr s.c. However, administration of 0.06, 0.2, and 0.6 mg/rat/hr s.c. midazolam did not induce analgesia in rats, Additionally, plasma drug concentration increased dose-dependently 2 weeks after the start of administration. Therefore, 2-week continuous subcutaneous infusion of midazolam produces sedation, but not analgesia, in rats. The onset rate and magnitude of this effect is dose dependent, but remains essentially constant for a given dose throughout the administration period. These results suggest that continuous infusion of midazolam causes sedation that could be maintained safely for 2 weeks. (author abst.) |
|
|
|
Related Articles;
|
|
